Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

orld territories. We expect a license agreement or agreements with up-front payment(s), milestones and royalty terms to be completed after positive CLIRS trial results.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences ("Cutanea"), our development and commercialization partner for CLS001, is preparing to initiate its Phase III clinical program. As part of its plan to submit a NDA in 2011, Cutanea expects:

- in the first quarter of calendar 2009, to initiate chronic toxicology

studies, specifically the required dermal carcinogenicity study,

which Cutanea expects will be the rate limiting activity for

submission of the NDA; and

- in the second half of calendar 2009, to initiate its Phase III

clinical study program (previously Cutanea was targeting the end of

2008).

Celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Following the report of interim results from a Phase II viral kinetics study of hepatitis C virus treatment-nave patients in July 2008, we are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): MX-2401, an injectable lipopeptide, is being developed for the treatment of serious gram positive bacterial infections, including highly publicized treatment resistant hospital bacteria such as MRSA. We expect MX- 2401 to be our next clinical candidate as it represents a highly competitive intravenous agent for treating serious infections caused by drug-resistant bacteria for which there are currently very few effective solutions. With a view to our current financial resources, the focus of activities in this program is to increase the level of business development and scientific publication initiatives, includin
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... CA (PRWEB) December 18, 2014 With ... limited time special on Sartorius Biohit products . ... on mLINE pipettes, Picus Electronic Pipette Trade-in Program, and ... Health and Safety officers around the world. They are ... pipetting. Other features include:, ,     Full volume ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 7, 2011 DuPont (NYSE: DD ) ... at the JPMorgan Diversified Industries Conference to expect attractive ... selective investment in attractive areas, broad-based growth, especially in ... also reaffirmed DuPont,s 2011 earnings per share (EPS) outlook ...
... June 7, 2011 Infrared Systems International (OTCBB: IFRS) is ... a pilot study of its NatuRx™ HIV/AIDS treatment and will ... AquaLiv concluded a pilot study with two HIV/AIDS ... anniversary of the first reported AIDS victims on June 5th, ...
... its origins in Hamburg. Jrg Weimller, a materials scientist ... Helmholtz Center Geesthacht, has carried out research on this ... Institute for Metal Research in Shenyang, China., The 51-year-old ... which opens the door to a multitude of diverse ...
Cached Biology Technology:DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3Hard or soft: At the touch of a button 2Hard or soft: At the touch of a button 3
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... fish is good for our brains and memory. But what ... fish, that makes our memory sharper? Medical researchers at ... published their findings in the peer-reviewed journal Applied Physiology, ... his team discovered lab models fed a high-DHA diet had ...
... Steve Moose, an associate professor of maize functional genomics at ... think they may have discovered a new source of heterosis, ... small RNAs (sRNAs), a class of double-stranded RNA molecules that ... refers to the increased vigor or general health, resistance to ...
... the Royal Astronomical Society (RAS) announced a new publishing ... prestigious journals. OUP will assume publication of ... Monthly Notices of the Royal Astronomical Society: Letters , ... Geophysics from January 2013. Professor David Southwood, ...
Cached Biology News:A new source of maize hybrid vigor 2A new source of maize hybrid vigor 3Royal Astronomical Society and Oxford University Press partnership announced 2
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
ANTI S. GROUP AG:H...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: